Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) (CPD)
A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS
Sponsor: European Myeloma Network B.V.
Listed as NCT02185820, this PHASE1/PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by European Myeloma Network B.V., it has been updated 11 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Aug 2023 — Mar 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Apr 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Myeloma Network B.V.
- University of Turin, Italy
For direct contact, visit the study record on ClinicalTrials.gov .